Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Essential Thrombocythemia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Essential Thrombocythemia - Pipeline Review, H2 2015', provides an overview of the Essential Thrombocythemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Essential Thrombocythemia Overview 6 Therapeutics Development 7 Pipeline Products for Essential Thrombocythemia - Overview 7 Essential Thrombocythemia - Therapeutics under Development by Companies 8 Essential Thrombocythemia - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Essential Thrombocythemia - Products under Development by Companies 11 Essential Thrombocythemia - Companies Involved in Therapeutics Development 12 Aop Orphan Pharmaceuticals AG 12 Galena Biopharma, Inc. 13 Incyte Corporation 14 Italfarmaco S.p.A. 15 Novartis AG 16 Onconova Therapeutics, Inc. 17 PharmaEssentia Corporation 18 Essential Thrombocythemia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 anagrelide hydrochloride CR - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 anagrelide hydrochloride PR - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 erismodegib - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 givinostat - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 rigosertib sodium - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ropeginterferon alfa-2b - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ruxolitinib phosphate - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Essential Thrombocythemia - Recent Pipeline Updates 49 Essential Thrombocythemia - Dormant Projects 68 Essential Thrombocythemia - Discontinued Products 69 Essential Thrombocythemia - Product Development Milestones 70 Featured News & Press Releases 70 Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 70 Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 70 Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 71 May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 73 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Essential Thrombocythemia, H2 2015 7 Number of Products under Development by Companies, H2 2015 8 Comparative Analysis by Late Stage Development, H2 2015 9 Comparative Analysis by Clinical Stage Development, H2 2015 10 Products under Development by Companies, H2 2015 11 Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H2 2015 12 Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H2 2015 13 Essential Thrombocythemia - Pipeline by Incyte Corporation, H2 2015 14 Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H2 2015 15 Essential Thrombocythemia - Pipeline by Novartis AG, H2 2015 16 Essential Thrombocythemia - Pipeline by Onconova Therapeutics, Inc., H2 2015 17 Essential Thrombocythemia - Pipeline by PharmaEssentia Corporation, H2 2015 18 Assessment by Monotherapy Products, H2 2015 19 Number of Products by Stage and Target, H2 2015 21 Number of Products by Stage and Mechanism of Action, H2 2015 23 Number of Products by Stage and Molecule Type, H2 2015 27 Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H2 2015 49 Essential Thrombocythemia - Dormant Projects, H2 2015 68 Essential Thrombocythemia - Discontinued Products, H2 2015 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.